The role of dendritic cells in cancer.

The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123-178 Authors: Lee YS, Radford KJ Abstract Cancer immunotherapy harnesses the ability of the immune system to recognize and eliminate cancer. The potent ability of dendritic cells (DCs) to initiate and regulate adaptive immune responses underpins the successful generation of anti-tumor immune responses. DCs are a heterogeneous leukocyte population comprised of distinct subsets that drive specific types of immune responses. Understanding how DCs induce tumor immune responses and the mechanisms adopted by tumors to evade DC surveillance is essential to render immunotherapies more effective. This review discusses current knowledge of the roles played by different DC subsets in human cancer and how these might be manipulated as new immunotherapeutics to improve CD8+ T cell-mediated immune responses, with a particular focus on the conventional type 1 DCs (cDC1). PMID: 31810552 [PubMed - in process]
Source: International Review of Cell and Molecular Biology - Category: Cytology Authors: Tags: Int Rev Cell Mol Biol Source Type: research

Related Links:

The paper highlights the candidate ’s ability to target and shrink HPV motivated tumors in both animal studies and human blood samples.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Delivery of cellular immunotherapy (IMTX) in the ambulatory setting continues to evolve in an academic Comprehensive Cancer Center. A dedicated IMTX outpatient department (OPD) was opened in 2016 (patients treated=427), providing both FDA approved CAR T cell and phase l/ll immune effector cell treatments. Provision of care to acutely ill patients, ensuring early recognition of treatment related side effects, and triggering a prompt hospitalization when indicated, requires an intricate triage system.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 590 Source Type: research
Early detection of neurotoxicity (NT) and prompt intervention in patients receiving cellular immunotherapy products is crucial. Guidance on the type of neurologic assessment to be conducted has only recently been established. Previously inconsistent and infrequent assessments varied from institution and depended upon individual nurses ’ clinical experience with NT.  “ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells” was published in 2018 and a plan for implementation of a standardized NT nursing assessment was needed at a Comprehensiv...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 586 Source Type: research
A Comprehensive Cancer Center (CCC) providing cellular immunotherapy treatments developed a standardized discharge process to ensure optimal continuity of care following immune effector cell (IEC) therapy. As utilization of IEC therapies increases, it is imperative to have an outlined comprehensive discharge plan to promote continuity of care, treatment-specific follow up, and ensure both patient and referring provider feel confident to assume follow-up care. Nurses are pivotal to this process development and implementation.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 585 Source Type: research
In 2016, a Comprehensive Cancer Center opened an ambulatory cellular immunotherapy clinic, partnered with an inpatient facility for hospitalization. The center provides FDA Approved CAR T Cell therapies as well investigational immune effector cell (IEC) products under Phase I/II clinical trials. To optimize patient care, a multidisciplinary workgroup developed IEC specific standard of care guidelines. These standards facilitate alignment of care between sites and promotes collaboration between nurses and providers to enhance patient outcomes.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 600 Source Type: research
Cellular immunotherapy is a rapidly progressing field in multiple myeloma (MM). Multiple clinical trials have reported impressive efficacy of B cell maturation antigen (BCMA) directed chimeric antigen receptor cell therapy (BCMA CART) in MM. While trials demonstrated a high response rate, the durable response rate is around 30%. Most patients lose their CART cells, and the disease relapses within the first year, suggesting an inhibition by the MM tumor microenvironment (TME). Therefore strategies to overcome this inhibition would represent a major advance in this field.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 333 Source Type: research
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was approved by the FDA in October 2017 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer. Since the CAR-T modified cells multiply and persist in the patient's bloodstream, they have the potential to protect the patient against recurrence.Beginning October 1, 2017, two new, unique ICD-10 procedure codes were assigned to CAR-T immunotherapy (XW033C3 for peripheral venous route and XW...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 486 Source Type: research
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was first approved by the FDA in October 2017 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer.Cytokine release syndrome is a known serious adverse event after CAR-T infusion which results in symptoms including fever, nausea, headache, and hypotension. Tocilizumab is an anti-IL-6 receptor antagonist approved for the treatment of CRS in CAR-T patients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 477 Source Type: research
This is an unparalleled time in cancer research, particularly with the use of cellular therapeutics to target both solid and liquid tumors. This science is challenging the boundaries of clinical care to update guidelines, streamline processes, and integrate clinical and research teams.The University of Kansas Cancer Center was launched into the cell therapy space when we enrolled the first adult patient on Novartis Juliet CAR-T trial for DLBCL. Our team learned that inpatient and outpatient infrastructure and multidisciplinary collaboration are essential to promoting quality clinical care to complement this innovative new ...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 409 Source Type: research
Publication date: Available online 23 January 2020Source: Seminars in Cancer BiologyAuthor(s): Arthur Liu, Michael A. CurranAbstractAdvances in our understanding of tumor immune biology and development of cancer immunotherapies have led to improved outcomes for patients that suffer from aggressive cancers such as metastatic melanoma. Despite these advances, a significant proportion of patients still fail to benefit, and as a result, attention has shifted to understanding how cancer cells escape immune destruction. Of particular interest is the metabolic landscape of the tumor microenvironment, as recent studies have demons...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cytology | Immunotherapy | Molecular Biology